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Indirect immunofluorescent assay as an aid
in the diagnosis of suspected immune
mediated ataxias
Marios Hadjivassiliou1* , Graeme Wild2, Priya Shanmugarajah1, Richard A. Grünewald1 and Mohammed Akil3
Abstract
Background and purpose: Immune mediated cerebellar ataxias account for a substantial proportion of all
progressive ataxias. A diagnostic serological test is not always available. This is particularly problematic in Primary
Autoimmune Cerebellar Ataxia, hence the necessity for diagnostic criteria recently devised and published by an
International Task Force. We present our experience in the use of a commercially available indirect
immunofluorescence assay, intended to be used for the detection of antibodies associated with paraneoplastic
neurological syndromes.
Methods: Retrospective review of patients with ataxia who underwent serological testing using this assay as part of
their diagnostic evaluation. We were interested in 3 groups: suspected immune mediated ataxias, genetically confirmed
ataxias and patients with cerebellar variant of multi-system atrophy (MSA-C). The indirect immunofluorescence assay was
performed using commercially available monkey cerebellum slides and anti-human IgG FITC conjugated antiserum.
Results: A total of 300 patients that had this test and fitted into one of these 3 groups (immune ataxias 190, genetic
ataxias 60, MSA-C 50) were identified. The prevalence of positive immunofluorescence but negative immunoblot was
172/190 (91%) in the suspected immune ataxia group, 3/60 (5%) in the genetic group and 2/50 (4%) in the MSA-C group.
The difference between the first and the other groups was significant χ2 (1, N = 291) = 64.2, p < 00001.
Conclusions: This report demonstrates that a commercially available immunofluorescence assay can be used to provide
additional diagnostic aid for suspected immune mediated ataxias and in particular Primary Autoimmune Cerebellar Ataxia
where no diagnostic marker exists.
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Introduction
Immune mediated cerebellar ataxias (IMCA) account for
a substantial proportion of all progressive ataxias [1]. Ex-
amples of IMCA include Gluten Ataxia (GA), anti-GAD
ataxia, Paraneoplastic Cerebellar Degeneration (PCD)
and post-infectious cerebellitis. Unlike GA, PCD and
post-infectious cerebellitis, in which an antigenic trigger
is known, in some suspected autoimmune ataxias the
antigenic trigger is not known and any associated neur-
onal antibodies are not well characterized or of proven
pathogenicity. The term Primary Autoimmune Cerebellar
Ataxia (PACA) was introduced to describe this latter
group of patients [2].
It is very likely that a substantial number of patients
with late onset so called “idiopathic” sporadic ataxias
have PACA [1]. Recently an International Task Force on
IMCA published diagnostic criteria for PACA in order
to enable neurologists to consider this diagnosis [3]. The
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proposed diagnostic criteria for PACA are based on clin-
ical (mode of onset, pattern of cerebellar involvement,
presence of other autoimmune diseases), imaging find-
ings (MRI and if available MR spectroscopy showing
preferential, but not exclusive involvement of vermis)
and laboratory investigations (CSF pleocytosis and/or
CSF-restricted IgG oligoclonal bands) parameters. These
criteria are important because PACA is potentially treat-
able with immunosuppression [4].
Aside of the clinical criteria for the diagnosis of PACA,
investigations such as CSF examination (pleocytosis and/
or oligoclonal bands) and serological evidence of anti-
bodies associated with additional autoimmune diseases
(which can be a feature in PACA) can also be useful
clues to its diagnosis. However, so far there is no single
investigation that can be viewed as a reliable diagnostic
marker for PACA.
Here, we describe our observations and experience in
the use of a commercially available indirect immuno-
fluorescence assay using monkey cerebellum, originally
intended to be used for the detection of paraneoplastic




All patients reported here were attending the Sheffield
Ataxia Centre. They underwent a battery of investiga-
tions as part of their diagnostic workup for causes of
ataxia. Details of all these tests can be found in a previ-
ous publication from our group [1]. Genetic testing was
performed with next generation sequencing using a
panel of 175 ataxia genes (for details of the genes see
supplementary material).
The patient selection for this report was retrospective.
The selection was based on all patients with ataxia who
had undergone paraneoplastic antibody screening as part
of their ataxia diagnostic work up. All patients had com-
pleted their clinical evaluation and investigations (blood
tests, genetic tests and brain imaging) and had been (and
still are) followed up at regular intervals. We selected all
the patients that fell into 3 of the following groups:
(1). Patients with IMCA (gluten ataxia, anti-GAD ataxia,
or fulfilling the criteria for PACA). Those patients
already on immunosuppression or on gluten-free
diet at the time of the baseline testing were excluded.
We also excluded patients with PCD. Patients with
gluten ataxia by definition were positive for antigliadin
antibodies. Patients with anti-GAD ataxia were posi-
tive for anti-GAD antibodies (titre > 2000). Patients
with PACA fulfilled the published criteria for the diag-
nosis of PACA [3]. None of the patients in this IMCA
group were found to have an alternative explanation
for their ataxia. Detail clinical characterisation of these
3 different types of immune ataxias have already been
published [4–6].
(2). Patients with genetically confirmed ataxia.
(3). Patients with clinically probable cerebellar variant
of multiple system atrophy (MSA-C).
The rational for selecting patients in groups 2 and 3 was
for a suitable control groups of ataxia patients with differ-
ent pathogenesis (genetic or degenerative respectively).
Indirect immunofluorescence
The indirect immunofluorescence assay was performed
using commercially available monkey cerebellum slides
and anti-human IgG FITC conjugated antiserum (Inova
Diagnostics). Wells on the slides were flooded with 1/50
diluted samples in PBS. The slides were incubated for
30 min and then washed with PBS before flooding with
anti-human IgG FITC conjugated antiserum. Slides were
incubated for 30 min, washed again in PBS and then ex-
amined under a UV microscope at 470 nm. Cerebellar
auto-antibodies can be identified by their characteristic
fluorescent staining patterns: Yo - Cytoplasm of Purkinje
Cells, Hu - Cell nuclei of neurons in the CNS and PNS,
Amphiphysin - Membrane of synaptic vesicles, CV2 -
Cytoplasm of Oligodendrocytes, Ri - Cell nuclei of neu-
rons in the CNS, Tr - Cytoplasm of Purkinje cells and
dots in the molecular layer.
Positive immunofluorescent patterns were confirmed
by EUROLINE immunoblots (Euroimmun AG) on a
EUROBlotOne (Euroimmun AG) automated processor.
The EUROLINE immunoblot contains antigens for
Amphiphysin, CV2.1, PNMA2 (Ma2/Ta), Ri, Yo, and
Hu. Bands on the individual immunoblots are qualita-
tively reported according to their intensity. We interpret
the readings as 0 (negative) + (negative) and ++ (weak
positive) and +++ (positive). For the purpose of this re-
port the patients were divided into positive (++, +++) or
negative (no staining, +).
Positive fluorescence results on any sample with a
negative immunoblot were reported as per the pattern
seen (Yo-like, Hu-like etc).
Results
A total of 300 patients who underwent serological testing
for paraneoplastic antibodies using the above assay are in-
cluded in this report. Of these, 190 were considered as
having IMCA. This group included patients with gluten
ataxia (143), patients fulfilling the criteria for PACA (32)
and patients with anti-GAD ataxia (15). Group 2 consisted
of 60 patients who had a confirmed genetic diagnosis.
Group 3 consisted of 50 patients with clinically probable
MSA-C. The prevalence of positive immunofluorescence
but negative immunoblot was 172/190 (91%) in the
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suspected IMCA group, 3/60 (5%) in the genetic group
and 2/50 (4%) in the MSA-C group. The difference be-
tween the first group and the other 2 groups was signifi-
cant χ2 (1, N = 291) = 64.2, p < 00001. By far the
commonest pattern of staining in the positive cases was
Hu-like (141) followed by Yo-like (11). Much less com-
mon patterns included CV2-like, Ma2-like, amphyphysin-
like and Tr-like. Table 1 summarises the results.
Discussion
This report demonstrates for the first time that a com-
mercially available assay used in an NHS immunology
laboratory can be reliably used to provide further evi-
dence of a possible immune mediated pathogenesis in
the context of PACA.
Using a commercial indirect immunofluorescent assay
for the detection of well-characterised paraneoplastic
antibodies offered by our NHS immunology laboratory,
we have made the observation that sera from patients
with suspected immune ataxias show positive results in
91% as opposed to 5 and 4% in patients with ataxia due
to a genetic or a degenerative cause respectively. In none
of the positive patients was immunoblot positive (we
had excluded patients with PCD), in contrast to what is
seen in those cases of PCD. This readily available com-
mercial assay therefore provides a useful additional diag-
nostic aid for suspected IMCA. A positive result is
particularly helpful in the context of PACA where the
diagnosis relies on fulfilling recently published diagnostic
criteria but without any specific single test being
diagnostic.
The vast majority of positive results reported here showed
an immunoreactivity mimicking what is seen in anti-Hu
antibody related PCD (Fig. 1). Less common patterns seen
included anti-Yo, anti-CV2, anti-amphyphysin and anti-Tr
antibodies. However subsequent immunoblot was negative
for any of these antibodies, eliminating the likelihood of
PCD.
For patients with gluten ataxia and anti-GAD ataxia,
specific diagnostic markers already exist in the form of
antigliadin and/or TG6 antibodies and anti-GAD anti-
bodies respectively. The fact that sera from patients with
GA or anti-GAD ataxia demonstrate reactivity with cere-
bellar tissue also supports the fact that these ataxias are
indeed immune-mediated. Whilst further work on char-
acterising the specificity of antibody reactivity and
pathogenicity has already been done in the context of
GA and anti-GAD ataxia, this report highlights the util-
ity of a simple immunofluorescence assay as a useful tool
in raising the suspicion of immune mediated ataxias [7–
10]. This is particularly helpful in the context of PACA.
PACA is the term used to describe autoimmune ataxias
where the antigenic trigger is not known and any associ-
ated neuronal antibodies are not well-characterized or of
proven pathogenicity [3]. Whilst diagnostic criteria for
PACA have recently been published, any additional sero-
logical tests such as what has been described here may
be useful in increasing the diagnostic suspicion for
PACA.
A previous smaller study by our group, used an in-
house immunohistochemistry study and showed reactiv-
ity using rat cerebellum in 12/20 (60%) patients with
idiopathic sporadic ataxia (not necessarily selected for
the possibility of autoimmune pathogenesis) as opposed
to 1/20 (5%) in patients with genetic ataxias [11].
The expanding spectrum of cerebellar, and in particu-
lar Purkinje cell antibodies, in the context of both PCD
and other immune ataxias, has been highlighted in a
series of review articles by Jarius and Wildemann in
which they discus the clinical, oncological, therapeutic
and pathogenic features of the 12 most common Pur-
kinje cell antibodies [12]. Whilst very specialised
Table 1 summary of the immunofluorescence findings per group of patients with immune, genetic or degenerative ataxias
Immune mediated cerebellar ataxias (190 patients) Control groups of ataxias (110 patients)
Number of patients positive
on immunofluorescence
(percentage positive)
172/190 (91%) 5/110 (5%)
Ataxia subgroups
(number of patients)













126/143 (88%) 32/32 (100%) 14/15 (93%) 3/60 (5%) 2/40 (4%)
Type of staining per group
(percentage from positive
patients)
Hu like 109/126 (87%)
Yo like 7/126 (6%)
CV2 like 4/126 (3%)
amphiphysin like
3/126 (2%)
Tr like 2/126 (2%)
Ma2 like 1/126 (1%)
Hu like 26/32 (81%)
Yo like 4/32 (13%)
(one had both Hu and
Yo like staining)
amphiphysin like 2/32 (6%)





Hu like 2/3 (66%)
Yo like 1/3 (33%)
Hu like 1/2 (50%)
amphiphysin like 1/2
(50%)
Hadjivassiliou et al. Cerebellum & Ataxias             (2021) 8:6 Page 3 of 4
immunological laboratories can offer such a service, ac-
cessibility to such testing is limited for most neurologists
who encounter a patient with potentially immune medi-
ated ataxia. Furthermore, by definition PACA is not as-
sociated with such pathogenic antibodies but is likely to
represent a heterogeneous entity of immune-mediated
ataxias for which, so far, no specific pathogenic anti-
bodies have been described.
In summary we present our data based on a large co-
hort of patients with ataxia who were tested using a
commercial immunofluorescence assay, demonstrating
the presence of reactivity using monkey cerebellar tissue
in those patients with IMCA. Such reactivity was rare in
genetic and degenerative ataxias and as such this com-
mercially available assay can be a useful and practical
screening tool, particularly for patients suspected of hav-
ing PACA where a single diagnostic marker does not
exist.
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Fig. 1 An example of a Hu like immunofluorescence staining
(arrows) from a patient with suspected immune mediated ataxia.
Immunoblot was negative for anti-Hu. This pattern of staining was
the commonest observed in all the immune ataxia groups
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